Atomi Financial Group Inc. Makes New Investment in argenx SE (NASDAQ:ARGX)

Atomi Financial Group Inc. purchased a new position in shares of argenx SE (NASDAQ:ARGX) during the 4th quarter, Holdings Channel.com reports. The fund purchased 551 shares of the company’s stock, valued at approximately $339,000.

Several other large investors have also recently made changes to their positions in the business. Raymond James Trust N.A. raised its stake in shares of argenx by 6.0% during the third quarter. Raymond James Trust N.A. now owns 495 shares of the company’s stock worth $268,000 after acquiring an additional 28 shares in the last quarter. Hantz Financial Services Inc. increased its stake in shares of argenx by 8.9% in the third quarter. Hantz Financial Services Inc. now owns 528 shares of the company’s stock worth $286,000 after buying an additional 43 shares during the period. Aaron Wealth Advisors LLC increased its stake in shares of argenx by 10.1% in the fourth quarter. Aaron Wealth Advisors LLC now owns 489 shares of the company’s stock worth $301,000 after buying an additional 45 shares during the period. GAMMA Investing LLC increased its stake in shares of argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after buying an additional 56 shares during the period. Finally, Cromwell Holdings LLC increased its stake in shares of argenx by 73.3% in the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after buying an additional 66 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Price Performance

Shares of argenx stock opened at $648.94 on Friday. The stock has a market cap of $39.18 billion, a price-to-earnings ratio of -737.43 and a beta of 0.59. The firm’s 50-day moving average is $625.94 and its 200 day moving average is $563.70. argenx SE has a 1 year low of $349.86 and a 1 year high of $678.21.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. The company had revenue of $588.88 million for the quarter, compared to analysts’ expectations of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same quarter in the previous year, the business posted ($1.25) EPS. On average, equities analysts expect that argenx SE will post 2.78 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ARGX shares. Wedbush reaffirmed an “outperform” rating and issued a $655.00 target price on shares of argenx in a research note on Tuesday, December 3rd. Robert W. Baird downgraded shares of argenx from an “outperform” rating to a “neutral” rating and lifted their target price for the stock from $515.00 to $650.00 in a research note on Friday, November 1st. Wolfe Research raised shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 target price on the stock in a research note on Tuesday, November 12th. Raymond James reissued a “strong-buy” rating and set a $605.00 price objective on shares of argenx in a research report on Thursday, October 10th. Finally, Guggenheim boosted their price objective on shares of argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $658.39.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.